Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

XyloCor Therapeutics

Request full access

Focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease

Upper Merion Township, United StatesFounded 2013Biotech & Life Sciences

About XyloCor Therapeutics

XyloCor Therapeutics is a biotechnology company dedicated to enhancing the lives of individuals suffering from cardiovascular disease through the advancement of gene therapy. The company specializes in developing gene therapy treatments specifically for advanced coronary artery disease, a severe condition that affects the heart's blood vessels. XyloCor's innovative approach is rooted in proprietary gene therapy technologies developed in collaboration with Weill Cornell Medical College.

The primary clients of XyloCor are patients with advanced coronary artery disease, a demographic that often has limited treatment options. The company operates within the biotechnology and healthcare markets, focusing on cutting-edge medical research and development.

XyloCor's business model revolves around the research, development, and eventual commercialization of gene therapy products. Revenue is generated through a combination of research grants, partnerships with medical institutions, and future sales of their gene therapy treatments once they receive regulatory approval.

By addressing a critical unmet need in cardiovascular health, XyloCor aims to provide a transformative impact on patient outcomes.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
80.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2025 $68M $270M Fountain Healthcare Partners · Jeito Capital · EQT Life Sciences · Lumira Ventures ↗
SERIES AOther financing Mar 2021 $23M $90M Longwood Fund · Lumira Ventures · Fountain Healthcare Partners · EQT Life Sciences —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

XyloCor Therapeutics website traffic

Latest recorded traffic for XyloCor Therapeutics is 2K monthly website visits, up 81.8% over the last three months. XyloCor Therapeutics's team grew 12.5% over the past year.

Latest monthly visits2K 3-month web change+81.8% 1-year team growth+12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
ClotProtect TherapeuticsNovel anti-fibrinolytic treatment enhancing clot formation for acute haemorrhage with superior efficacy Leeds, United Kingdom Operational — $1.9M $6.4M
SpectrawaveDiagnosis and treatment of cardiovascular disease through the development of innovative optical diagnostic and therapeutic devices Waltham, United States Acquired
Zensun (Shanghai) Sci & TechA biopharmaceutical company focusing on the development of innovative bio-therapeutic Huangpu, China Operational
Aderis PharmaceuticalsAderis Pharmaceuticals focused on discovery, development and commercialization of products for the diagnosis Hopkinton, United States Acquired
Micell TechnologiesBiomedical device company developing interventional cardiology systems for vascular drug delivery Durham, United States Operational
BioTrace MedicalBioTrace Medical, Inc is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs San Carlos, United States Operational
VentrinovaVentriNova is revolutionizing cardiac regenerative medicine by reversing cardiac damage pharmacologically New York City, United States Operational
VenoStentBiomaterial platform and medical device company that has developed an external stent using shape memory polymers Houston, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

XyloCor Therapeutics in the Upper Merion Township ecosystem

Live from Dealroom

The XyloCor Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • EQT Life Sciences
  • Sofinnova Investments
  • Fountain Healthcare Partners
  • Longwood Fund
  • Lumira Ventures
  • Jeito Capital

Other known investors2 additional known investors

  • Cornell Tech
  • Cornell University
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States84.6%
🇳🇱 Netherlands7.7%
🇬🇧 United Kingdom7.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about XyloCor Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See XyloCor Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.